Dark
Streaming/Mobile
OldĀ Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
18:03:17 EDT Tue 30 Apr 2024
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR Search
SEDAR Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login to Stockwatch
Q:NKTR
- NEKTAR THERAPEUTICS -
http://www.nektar.com
18:03:17 EDT
Sym-X
Bid - Ask
Last
Chg
%Ch
Vol
$Vol
#Tr
Open-Hi-Lo
Year Hi-Lo
Last Tr
News
Delay
NKTR
- Q
0.4
1.44
·
1.55
0.4
1.46
814.4
1,013
3,209
1.45
1.52
1.40
1.75 0.4126
17:33:13
Mar 22
15 min
RT 2¢
Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Nasdaq Indicators -- Market:
Nasdaq
-- Bid Tick:
Down
-- UPC Restricted:
No
Fundamentals
·
Holders
·
Trade Workstation
·
Market Depth
·
3 Month Closes
·
Technical Charts
1 yr
|
2 yr
|
3 yr
|
5 yr
|
10 yr
|
15 yr
|
20 yr
·
Live Charts
1 yr
|
1 day
·
1yr Bulletins
·
Historical
·
Options
·
Portfolio
Recent Trades - Last 10 of 3209
More trades...
Time ET
Ex
Price
Change
Volume
17:33:13
Q
1.44
-0.02
5
17:13:06
Q
1.44
-0.02
12
16:52:37
Q
1.50
0.04
300
16:37:51
Q
1.50
0.04
100
16:03:36
Q
1.4516
-0.0084
1
16:00:01
Q
1.46
800
16:00:01
Q
1.46
700
16:00:01
Q
1.46
44
16:00:01
Q
1.46
280
16:00:01
Q
1.46
265
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
Recent Bulletins
News Releases
In The News
Other
Date ET
Symbol
Type
Headline
2024-03-22 14:00
U:NKTR
News Release
200
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
2024-03-05 09:00
U:NKTR
News Release
200
Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata
2024-03-04 16:15
U:NKTR
News Release
200
Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
2024-03-04 08:30
U:NKTR
News Release
200
Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX
2024-02-27 18:00
U:NKTR
News Release
200
Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference
2024-02-26 18:00
U:NKTR
News Release
200
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets
2024-01-03 18:00
U:NKTR
News Release
200
Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
2023-12-11 18:00
U:NKTR
News Release
200
Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting
2023-11-07 16:15
U:NKTR
News Release
200
Nektar Therapeutics Reports Third Quarter 2023 Financial Results
2023-10-31 18:00
U:NKTR
News Release
200
Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets
2023-10-13 08:30
U:NKTR
News Release
200
Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress
2023-10-02 09:00
U:NKTR
News Release
200
Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy
2023-09-27 09:00
U:NKTR
News Release
200
Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer
2023-09-13 09:00
U:NKTR
News Release
200
Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
2023-09-06 18:00
U:NKTR
News Release
200
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th
2023-08-08 16:15
U:NKTR
News Release
200
Nektar Therapeutics Reports Second Quarter 2023 Financial Results
2023-08-07 06:30
U:NKTR
News Release
200
Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company
2023-08-01 18:00
U:NKTR
News Release
200
Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets
2023-06-12 18:00
U:NKTR
News Release
200
Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference
2023-05-09 16:15
U:NKTR
News Release
200
Nektar Therapeutics Reports First Quarter 2023 Financial Results